Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 170

1.

Hematologic safety of chronic brain-penetrating erythropoietin dosing in APP/PS1 mice.

Sun J, Yang J, Whitman K, Zhu C, Cribbs DH, Boado RJ, Pardridge WM, Sumbria RK.

Alzheimers Dement (N Y). 2019 Oct 17;5:627-636. doi: 10.1016/j.trci.2019.09.003. eCollection 2019.

2.

Plasma Pharmacokinetics of High-Affinity Transferrin Receptor Antibody-Erythropoietin Fusion Protein is a Function of Effector Attenuation in Mice.

Sun J, Boado RJ, Pardridge WM, Sumbria RK.

Mol Pharm. 2019 Aug 5;16(8):3534-3543. doi: 10.1021/acs.molpharmaceut.9b00369. Epub 2019 Jun 27.

PMID:
31199881
3.

Blood-Brain Barrier Transport, Plasma Pharmacokinetics, and Neuropathology Following Chronic Treatment of the Rhesus Monkey with a Brain Penetrating Humanized Monoclonal Antibody Against the Human Transferrin Receptor.

Pardridge WM, Boado RJ, Patrick DJ, Ka-Wai Hui E, Lu JZ.

Mol Pharm. 2018 Nov 5;15(11):5207-5216. doi: 10.1021/acs.molpharmaceut.8b00730. Epub 2018 Sep 27.

PMID:
30226787
4.

Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial.

Giugliani R, Giugliani L, de Oliveira Poswar F, Donis KC, Corte AD, Schmidt M, Boado RJ, Nestrasil I, Nguyen C, Chen S, Pardridge WM.

Orphanet J Rare Dis. 2018 Jul 5;13(1):110. doi: 10.1186/s13023-018-0849-8.

5.

Plasma Pharmacokinetics of Valanafusp Alpha, a Human Insulin Receptor Antibody-Iduronidase Fusion Protein, in Patients with Mucopolysaccharidosis Type I.

Pardridge WM, Boado RJ, Giugliani R, Schmidt M.

BioDrugs. 2018 Apr;32(2):169-176. doi: 10.1007/s40259-018-0264-7.

PMID:
29442294
6.

Reduction in Brain Heparan Sulfate with Systemic Administration of an IgG Trojan Horse-Sulfamidase Fusion Protein in the Mucopolysaccharidosis Type IIIA Mouse.

Boado RJ, Lu JZ, Hui EK, Pardridge WM.

Mol Pharm. 2018 Feb 5;15(2):602-608. doi: 10.1021/acs.molpharmaceut.7b00958. Epub 2017 Dec 29.

PMID:
29251941
7.

Blood-Brain Barrier Penetrating Biologic TNF-α Inhibitor for Alzheimer's Disease.

Chang R, Knox J, Chang J, Derbedrossian A, Vasilevko V, Cribbs D, Boado RJ, Pardridge WM, Sumbria RK.

Mol Pharm. 2017 Jul 3;14(7):2340-2349. doi: 10.1021/acs.molpharmaceut.7b00200. Epub 2017 May 31.

PMID:
28514851
8.

Brain and Organ Uptake in the Rhesus Monkey in Vivo of Recombinant Iduronidase Compared to an Insulin Receptor Antibody-Iduronidase Fusion Protein.

Boado RJ, Pardridge WM.

Mol Pharm. 2017 Apr 3;14(4):1271-1277. doi: 10.1021/acs.molpharmaceut.6b01166. Epub 2017 Mar 16.

PMID:
28279069
9.

Very High Plasma Concentrations of a Monoclonal Antibody against the Human Insulin Receptor Are Produced by Subcutaneous Injection in the Rhesus Monkey.

Boado RJ, Hui EK, Lu JZ, Pardridge WM.

Mol Pharm. 2016 Sep 6;13(9):3241-6. doi: 10.1021/acs.molpharmaceut.6b00456. Epub 2016 Aug 19.

PMID:
27513815
10.

Insulin Receptor Antibody-α-N-Acetylglucosaminidase Fusion Protein Penetrates the Primate Blood-Brain Barrier and Reduces Glycosoaminoglycans in Sanfilippo Type B Fibroblasts.

Boado RJ, Lu JZ, Hui EK, Lin H, Pardridge WM.

Mol Pharm. 2016 Apr 4;13(4):1385-92. doi: 10.1021/acs.molpharmaceut.6b00037. Epub 2016 Mar 2.

PMID:
26910785
11.

Insulin receptor antibody-sulfamidase fusion protein penetrates the primate blood-brain barrier and reduces glycosoaminoglycans in Sanfilippo type A cells.

Boado RJ, Lu JZ, Hui EK, Pardridge WM.

Mol Pharm. 2014 Aug 4;11(8):2928-34. doi: 10.1021/mp500258p. Epub 2014 Jun 26.

12.

Insulin receptor antibody-iduronate 2-sulfatase fusion protein: pharmacokinetics, anti-drug antibody, and safety pharmacology in Rhesus monkeys.

Boado RJ, Ka-Wai Hui E, Zhiqiang Lu J, Pardridge WM.

Biotechnol Bioeng. 2014 Nov;111(11):2317-25. doi: 10.1002/bit.25289. Epub 2014 Aug 5.

13.

Blood-brain barrier molecular trojan horse enables imaging of brain uptake of radioiodinated recombinant protein in the rhesus monkey.

Boado RJ, Hui EK, Lu JZ, Sumbria RK, Pardridge WM.

Bioconjug Chem. 2013 Oct 16;24(10):1741-9. doi: 10.1021/bc400319d. Epub 2013 Oct 3.

PMID:
24059813
14.
15.

Combination stroke therapy in the mouse with blood-brain barrier penetrating IgG-GDNF and IgG-TNF decoy receptor fusion proteins.

Sumbria RK, Boado RJ, Pardridge WM.

Brain Res. 2013 Apr 24;1507:91-6. doi: 10.1016/j.brainres.2013.02.022. Epub 2013 Feb 18.

PMID:
23428543
16.

Pharmacokinetics and brain uptake of an IgG-TNF decoy receptor fusion protein following intravenous, intraperitoneal, and subcutaneous administration in mice.

Sumbria RK, Zhou QH, Hui EK, Lu JZ, Boado RJ, Pardridge WM.

Mol Pharm. 2013 Apr 1;10(4):1425-31. doi: 10.1021/mp400004a. Epub 2013 Feb 28.

17.

IgG-enzyme fusion protein: pharmacokinetics and anti-drug antibody response in rhesus monkeys.

Boado RJ, Hui EK, Lu JZ, Pardridge WM.

Bioconjug Chem. 2013 Jan 16;24(1):97-104. doi: 10.1021/bc3005123. Epub 2012 Dec 31.

18.

Pharmacokinetics and brain uptake in the rhesus monkey of a fusion protein of arylsulfatase a and a monoclonal antibody against the human insulin receptor.

Boado RJ, Lu JZ, Hui EK, Sumbria RK, Pardridge WM.

Biotechnol Bioeng. 2013 May;110(5):1456-65. doi: 10.1002/bit.24795. Epub 2012 Dec 25.

19.

Immunologic privilege in the central nervous system and the blood-brain barrier.

Muldoon LL, Alvarez JI, Begley DJ, Boado RJ, Del Zoppo GJ, Doolittle ND, Engelhardt B, Hallenbeck JM, Lonser RR, Ohlfest JR, Prat A, Scarpa M, Smeyne RJ, Drewes LR, Neuwelt EA.

J Cereb Blood Flow Metab. 2013 Jan;33(1):13-21. doi: 10.1038/jcbfm.2012.153. Epub 2012 Oct 17. Review.

20.

Selective plasma pharmacokinetics and brain uptake in the mouse of enzyme fusion proteins derived from species-specific receptor-targeted antibodies.

Zhou QH, Boado RJ, Pardridge WM.

J Drug Target. 2012 Sep;20(8):715-9. doi: 10.3109/1061186X.2012.712132.

PMID:
22845843
21.

Glycemic control and chronic dosing of rhesus monkeys with a fusion protein of iduronidase and a monoclonal antibody against the human insulin receptor.

Boado RJ, Hui EK, Lu JZ, Pardridge WM.

Drug Metab Dispos. 2012 Oct;40(10):2021-5. doi: 10.1124/dmd.112.046375. Epub 2012 Jul 20.

22.

Brain protection from stroke with intravenous TNFα decoy receptor-Trojan horse fusion protein.

Sumbria RK, Boado RJ, Pardridge WM.

J Cereb Blood Flow Metab. 2012 Oct;32(10):1933-8. doi: 10.1038/jcbfm.2012.97. Epub 2012 Jun 20.

23.

Imaging amyloid plaque in Alzheimer's disease brain with a biotinylated Aβ peptide radiopharmaceutical conjugated to an IgG-avidin fusion protein.

Sumbria RK, Boado RJ, Pardridge WM.

Bioconjug Chem. 2012 Jun 20;23(6):1318-21. doi: 10.1021/bc3001744. Epub 2012 Jun 6.

PMID:
22624578
24.

Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier.

Pardridge WM, Boado RJ.

Methods Enzymol. 2012;503:269-92. doi: 10.1016/B978-0-12-396962-0.00011-2. Review.

PMID:
22230573
25.

The Trojan Horse Liposome Technology for Nonviral Gene Transfer across the Blood-Brain Barrier.

Boado RJ, Pardridge WM.

J Drug Deliv. 2011;2011:296151. doi: 10.1155/2011/296151. Epub 2011 Nov 16.

26.

Brain-penetrating IgG-iduronate 2-sulfatase fusion protein for the mouse.

Zhou QH, Boado RJ, Lu JZ, Hui EK, Pardridge WM.

Drug Metab Dispos. 2012 Feb;40(2):329-35. doi: 10.1124/dmd.111.042903. Epub 2011 Nov 7.

PMID:
22065691
27.

Neuroprotection with a brain-penetrating biologic tumor necrosis factor inhibitor.

Zhou QH, Sumbria R, Hui EK, Lu JZ, Boado RJ, Pardridge WM.

J Pharmacol Exp Ther. 2011 Nov;339(2):618-23. doi: 10.1124/jpet.111.185876. Epub 2011 Aug 10.

28.

Delivery of a peptide radiopharmaceutical to brain with an IgG-avidin fusion protein.

Zhou QH, Lu JZ, Hui EK, Boado RJ, Pardridge WM.

Bioconjug Chem. 2011 Aug 17;22(8):1611-8. doi: 10.1021/bc200174x. Epub 2011 Jul 6.

29.

Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein.

Boado RJ, Hui EK, Lu JZ, Zhou QH, Pardridge WM.

Mol Pharm. 2011 Aug 1;8(4):1342-50. doi: 10.1021/mp200136x. Epub 2011 Jun 17.

PMID:
21667973
30.

Chronic dosing of mice with a transferrin receptor monoclonal antibody-glial-derived neurotrophic factor fusion protein.

Zhou QH, Boado RJ, Hui EK, Lu JZ, Pardridge WM.

Drug Metab Dispos. 2011 Jul;39(7):1149-54. doi: 10.1124/dmd.111.038349. Epub 2011 Apr 18.

31.

Expression in CHO cells and pharmacokinetics and brain uptake in the Rhesus monkey of an IgG-iduronate-2-sulfatase fusion protein.

Lu JZ, Boado RJ, Hui EK, Zhou QH, Pardridge WM.

Biotechnol Bioeng. 2011 Aug;108(8):1954-64. doi: 10.1002/bit.23118. Epub 2011 Mar 15.

32.

Brain penetrating IgG-erythropoietin fusion protein is neuroprotective following intravenous treatment in Parkinson's disease in the mouse.

Zhou QH, Hui EK, Lu JZ, Boado RJ, Pardridge WM.

Brain Res. 2011 Mar 25;1382:315-20. doi: 10.1016/j.brainres.2011.01.061. Epub 2011 Jan 26.

33.

Receptor-mediated abeta amyloid antibody targeting to Alzheimer's disease mouse brain.

Zhou QH, Fu A, Boado RJ, Hui EK, Lu JZ, Pardridge WM.

Mol Pharm. 2011 Feb 7;8(1):280-5. doi: 10.1021/mp1003515. Epub 2010 Dec 21.

34.

Neuroprotection in stroke in the mouse with intravenous erythropoietin-Trojan horse fusion protein.

Fu A, Hui EK, Lu JZ, Boado RJ, Pardridge WM.

Brain Res. 2011 Jan 19;1369:203-7. doi: 10.1016/j.brainres.2010.10.097. Epub 2010 Oct 31.

PMID:
21047502
35.

Brain-penetrating tumor necrosis factor decoy receptor in the mouse.

Zhou QH, Boado RJ, Hui EK, Lu JZ, Pardridge WM.

Drug Metab Dispos. 2011 Jan;39(1):71-6. doi: 10.1124/dmd.110.036012. Epub 2010 Sep 30.

36.

Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse.

Zhou QH, Boado RJ, Lu JZ, Hui EK, Pardridge WM.

Mol Pharm. 2010 Dec 6;7(6):2148-55. doi: 10.1021/mp1001763. Epub 2010 Oct 7.

PMID:
20860349
37.

Neuroprotection in experimental stroke in the rat with an IgG-erythropoietin fusion protein.

Fu A, Hui EK, Lu JZ, Boado RJ, Pardridge WM.

Brain Res. 2010 Nov 11;1360:193-7. doi: 10.1016/j.brainres.2010.09.009. Epub 2010 Sep 9.

PMID:
20833153
38.

CHO cell expression, long-term stability, and primate pharmacokinetics and brain uptake of an IgG-paroxonase-1 fusion protein.

Boado RJ, Hui EK, Lu JZ, Pardridge WM.

Biotechnol Bioeng. 2011 Jan;108(1):186-96. doi: 10.1002/bit.22907.

PMID:
20803562
39.

Intravenous treatment of experimental Parkinson's disease in the mouse with an IgG-GDNF fusion protein that penetrates the blood-brain barrier.

Fu A, Zhou QH, Hui EK, Lu JZ, Boado RJ, Pardridge WM.

Brain Res. 2010 Sep 17;1352:208-13. doi: 10.1016/j.brainres.2010.06.059. Epub 2010 Jun 30.

40.

Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse.

Boado RJ, Hui EK, Lu JZ, Pardridge WM.

J Pharmacol Exp Ther. 2010 Jun;333(3):961-9. doi: 10.1124/jpet.109.165092. Epub 2010 Mar 16.

PMID:
20233799
41.

Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein.

Boado RJ, Hui EK, Lu JZ, Zhou QH, Pardridge WM.

J Biotechnol. 2010 Mar;146(1-2):84-91. doi: 10.1016/j.jbiotec.2010.01.011. Epub 2010 Jan 25.

42.

Monoclonal antibody-glial-derived neurotrophic factor fusion protein penetrates the blood-brain barrier in the mouse.

Zhou QH, Boado RJ, Lu JZ, Hui EK, Pardridge WM.

Drug Metab Dispos. 2010 Apr;38(4):566-72. doi: 10.1124/dmd.109.031534. Epub 2010 Jan 14.

43.

Genetic engineering of a bifunctional IgG fusion protein with iduronate-2-sulfatase.

Lu JZ, Hui EK, Boado RJ, Pardridge WM.

Bioconjug Chem. 2010 Jan;21(1):151-6. doi: 10.1021/bc900382q.

PMID:
20000684
44.

Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor.

Boado RJ, Zhou QH, Lu JZ, Hui EK, Pardridge WM.

Mol Pharm. 2010 Feb 1;7(1):237-44. doi: 10.1021/mp900235k.

45.

Genetic engineering of IgG-glucuronidase fusion proteins.

Boado RJ, Pardridge WM.

J Drug Target. 2010 Apr;18(3):205-11. doi: 10.3109/10611860903353362.

46.
47.

Comparison of blood-brain barrier transport of glial-derived neurotrophic factor (GDNF) and an IgG-GDNF fusion protein in the rhesus monkey.

Boado RJ, Pardridge WM.

Drug Metab Dispos. 2009 Dec;37(12):2299-304. doi: 10.1124/dmd.109.028787. Epub 2009 Sep 9.

48.

AGT-181: expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in Rhesus monkeys.

Boado RJ, Hui EK, Lu JZ, Pardridge WM.

J Biotechnol. 2009 Oct 26;144(2):135-41. doi: 10.1016/j.jbiotec.2009.08.019. Epub 2009 Sep 6.

49.

Tumor necrosis factor receptor-IgG fusion protein for targeted drug delivery across the human blood-brain barrier.

Hui EK, Boado RJ, Pardridge WM.

Mol Pharm. 2009 Sep-Oct;6(5):1536-43. doi: 10.1021/mp900103n.

PMID:
19624167
50.

Pharmacokinetics and safety in rhesus monkeys of a monoclonal antibody-GDNF fusion protein for targeted blood-brain barrier delivery.

Pardridge WM, Boado RJ.

Pharm Res. 2009 Oct;26(10):2227-36. doi: 10.1007/s11095-009-9939-6. Epub 2009 Jul 17.

Supplemental Content

Loading ...
Support Center